Ovarian Cancer Action is proud to announce that it is the BioIndustry Association’s (BIA) chosen charity partner for 2021.
Founded over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.
Steve Bates OBE, Chief Executive of the BIA said: “We are delighted to be partnering with Ovarian Cancer Action for our 2021 Charity partnership. The charity does vital work to raise awareness and find treatments for ovarian cancer, and we will look to build understanding of their work in the UK life sciences sector, particularly through our 2021 Women in Biotech events and our virtual Gala Celebration in January.”
The BIA’s goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling their world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.
Cary Wakefield, CEO of Ovarian Cancer Action said: “A woman in the UK dies of ovarian cancer every two hours. It is an incredibly complex disease with shockingly low survival rates but we are committed to changing this for women affected, now and in the future.
Our partnership with the BIA will play a significant role in achieving our ambitions. We are extremely grateful for this opportunity and look forward to connecting with BIA's members and research networks to open up new collaborations and accelerate progress in research. Together, we can work towards a future where every woman survives ovarian cancer.”
To find out more about the research Ovarian Cancer Action funds, click here.
To find out more about BIA click here.